Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 520 
NEW HORIZON
Year : 2008  |  Volume : 14  |  Issue : 1  |  Page : 40-42

Sorafenib in the treatment of advanced hepatocellular carcinoma


Division of Gastroenterology and Hepatology, Department of Medicine, Riyadh Military Hospital, Riyadh, Saudi Arabia

Correspondence Address:
Ali Ben Mousa
Division of Gastroenterology and Hepatology, Department of Medicine, Riyadh Military Hospital, P.O. Box 7897, Riyadh 11159
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.37808

Rights and Permissions

Management of advanced hepatocellular carcinoma (HCC) is still a challenge to physicians since these patients are not candidates for surgical or ablative therapy. The disease carries a very poor prognosis with an expected survival of 4-6 months. No chemotherapeutic agent has been proven to improve the clinical outcome in such patients. A multikinase inhibitor, sorafenib, previously tested and found effective in other solid tumors recently found to significantly improve survival in patients with advanced HCC. Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis. It was well tolerated at a dose of 400 mg twice daily and permanent discontinuation of the drug was rarely required.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5382    
    Printed117    
    Emailed1    
    PDF Downloaded738    
    Comments [Add]    
    Cited by others 1    

Recommend this journal